小细胞肺癌治疗新进展
张爽， 程颖 - 中国肿瘤临床, 2021 - cjco.cn
小细胞肺癌(small cell lung cancer, SCLC) 治疗进展缓慢, 依托泊苷联合铂类和拓扑替康作为
SCLC 一线和二线治疗选择已经延续30 余年, 三线及以上SCLC 一直没有标准治疗方案. 因此 …
SCLC 一线和二线治疗选择已经延续30 余年, 三线及以上SCLC 一直没有标准治疗方案. 因此 …
Current status of clinical trials for small cell lung cancer
A Arcaro, B Fischer - Reviews on recent clinical trials, 2008 - ingentaconnect.com
SCLC represents 13% of all lung cancer cases and is the most aggressive form of lung
cancer with an overall 5-year survival less than 5%. The combination of cisplatin or …
cancer with an overall 5-year survival less than 5%. The combination of cisplatin or …
New advances in the treatment for small cell lung cancer
X Cui, P Song, L Zhang - Zhongguo fei ai za zhi= Chinese Journal …, 2019 - europepmc.org
小细胞肺癌 (small cell lung cancer, SCLC) 是一种恶性程度高, 病情进展快, 预后差,
易复发的难治性癌症. 在过去的 30 余年中, SCLC 以化疗和放疗为主的传统治疗策略并未出现 …
易复发的难治性癌症. 在过去的 30 余年中, SCLC 以化疗和放疗为主的传统治疗策略并未出现 …
Second-line chemotherapy for small-cell lung cancer: a review
CP Schultheis, MA Raheem, MC Perry - Clinical Lung Cancer, 2001 - Elsevier
Small-cell lung cancer (SCLC) is an aggressive malignancy, and only a minority of patients
survive 2 years. Although this cancer is sensitive to both chemotherapy and radiotherapy …
survive 2 years. Although this cancer is sensitive to both chemotherapy and radiotherapy …
小细胞肺癌治疗新进展
徐文鸿 - 国外医学(肿瘤学分册), 2002 - cqvip.com
肺癌中小细胞肺癌(SCLC) 恶性程度最高, 转移最早, 但目前由于对SCLC 生物行为的进一步认识
及新药的增多等原因, 能治愈的患者越来越多, 成为在一定程度上可治愈的肿瘤之一 …
及新药的增多等原因, 能治愈的患者越来越多, 成为在一定程度上可治愈的肿瘤之一 …
Small cell lung cancer: therapies and targets
RN Pillai, TK Owonikoko - Seminars in oncology, 2014 - Elsevier
Small cell lung cancer (SCLC) remains a fatal disease due to limited therapeutic options.
Systemic chemotherapy is the bedrock of treatment for both the limited and extensive stages …
Systemic chemotherapy is the bedrock of treatment for both the limited and extensive stages …
小细胞肺癌二线治疗的新进展
王阿曼， 蔡欣， 刘基巍 - 临床肿瘤学杂志, 2011 - cqvip.com
小细胞肺癌(SCLC) 是一种恶性程度极高且预后差的恶性肿瘤, 约占肺癌的15%~ 20%,
其初始对化疗敏感, 但极易复发. 复发后二线治疗的选择至今仍是难题, 目前尚无确切证据证实 …
其初始对化疗敏感, 但极易复发. 复发后二线治疗的选择至今仍是难题, 目前尚无确切证据证实 …
小细胞肺癌靶向药物研究进展
赵明芳， 刘云鹏 - 中国处方药, 2013 - cqvip.com
小细胞肺癌(SCLC) 占全部肺癌的15%-25%, 从EP 方案诞生至今, 化疗进展缓慢,
无论局限期还是广泛期, 预后极差, 局限期(LD) SCLC 的5 年生存率不足10%, 广泛期(ES) SCLC …
无论局限期还是广泛期, 预后极差, 局限期(LD) SCLC 的5 年生存率不足10%, 广泛期(ES) SCLC …
Treatment of small cell lung cancer
A Kurup, NH Hanna - Critical reviews in oncology/hematology, 2004 - Elsevier
The incidence of small cell lung cancer (SCLC) is declining in the United States (US). SCLC
is nearly universally smoking-related and is very sensitive to both chemotherapy and …
is nearly universally smoking-related and is very sensitive to both chemotherapy and …